Amgen Posts $6.45 Adjusted EPS for Third Quarter
AMGN sits 58% above its 52-week low of $292.12.
Summary
Amgen reported third-quarter adjusted EPS of $7.08, replacing the earlier $6.45 figure. The company guided full-year adjusted EPS to $22.90-$23.70 and full-year EPS to $18.34-$19.28. The print lands after a strong Q2 in August, when revenue of $10.1B beat estimates and full-year sales guidance was raised to $38.2-39.4B. Shares sit near the 52-week high of $475.645, so the bar for this quarter is elevated. The overhangs remain the FDA's proposal to withdraw Tavneos and the unresolved $10.7B IRS tax dispute. Full release details, including revenue and any further guidance revision, will determine whether this EPS line holds up.
At the time of this announcement, AMGN was trading at $460.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.4B. The 52-week trading range was $292.12 to $475.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.